🇺🇸 ABBV — AbbVie Inc.

Healthcare Compra
← Volver

Precio actual

256,46 USD

Máx. histórico

267,47

37 días

Caída desde máximo

-4,12%

Rango 52 semanas

190,75 – 267,47

Variación hoy

-1,44%

Cierre anterior

260,21

Rango de hoy

255,61 – 258,91

Volumen hoy

4.701.126

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
72,45 (puede no estar actualizado)
Dividend yield
2,70% (puede no estar actualizado)
Precio objetivo analistas
276,59 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 1 día
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,8300 USD · Yield: 2,66%
Fecha de pago Importe por participación
15/07/2026 1,7300 USD
15/04/2026 1,7300 USD
16/01/2026 1,7300 USD
15/10/2025 1,6400 USD
15/07/2025 1,6400 USD
15/04/2025 1,6400 USD
15/01/2025 1,6400 USD
15/10/2024 1,5500 USD
15/07/2024 1,5500 USD
12/04/2024 1,5500 USD
12/01/2024 1,5500 USD
12/10/2023 1,4800 USD
13/07/2023 1,4800 USD
13/04/2023 1,4800 USD
12/01/2023 1,4800 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
31/03/2017 65,46 65,52 65,15 65,16 -0,46% 0,57% 4.057.800
30/03/2017 65,76 65,82 65,25 65,46 -0,47% 0,87% 3.749.600
29/03/2017 65,95 66,27 65,68 65,77 -0,32% 0,89% 3.649.900
28/03/2017 65,96 66,21 65,64 65,98 -0,18% 0,86% 5.067.400
27/03/2017 65,37 66,28 65,24 66,10 +0,73% 1,59% 4.962.300
24/03/2017 65,51 66,11 65,32 65,62 -0,05% 1,21% 4.056.300
23/03/2017 65,52 66,07 65,36 65,65 +0,20% 1,08% 4.099.500
22/03/2017 65,38 65,73 65,10 65,52 +0,26% 0,96% 5.662.600
21/03/2017 65,96 66,00 65,04 65,35 -0,68% 1,46% 5.187.400
20/03/2017 65,78 66,01 65,56 65,80 +0,17% 0,68% 4.252.100
17/03/2017 66,04 66,09 65,50 65,69 -0,32% 0,89% 11.288.000
16/03/2017 66,40 66,45 65,55 65,90 -0,98% 1,36% 5.162.800
15/03/2017 65,70 66,79 65,68 66,55 +1,34% 1,69% 5.241.200
14/03/2017 65,88 66,05 65,60 65,67 -0,27% 0,68% 3.727.200
13/03/2017 65,87 65,94 65,30 65,85 -0,05% 0,97% 7.577.400
10/03/2017 65,30 66,45 65,11 65,88 +2,14% 2,05% 12.788.100
09/03/2017 64,14 64,72 64,05 64,50 +0,56% 1,04% 6.957.000
08/03/2017 63,75 64,68 63,50 64,14 +0,71% 1,85% 7.049.700
07/03/2017 63,14 64,14 62,97 63,69 +0,22% 1,85% 9.638.000
06/03/2017 63,00 63,85 62,88 63,55 +0,33% 1,54% 6.837.000
03/03/2017 63,11 63,53 62,83 63,34 +0,14% 1,11% 6.125.800
02/03/2017 62,78 63,60 62,60 63,25 +0,67% 1,59% 8.190.000
01/03/2017 62,16 62,93 61,95 62,83 +1,60% 1,58% 7.737.400
28/02/2017 62,11 62,40 61,69 61,84 -0,61% 1,14% 6.756.100
27/02/2017 62,02 62,37 61,68 62,22 +0,21% 1,11% 5.214.100
24/02/2017 61,92 62,23 61,49 62,09 +0,24% 1,20% 6.536.400
23/02/2017 61,68 62,24 61,45 61,94 +0,95% 1,28% 8.057.700
22/02/2017 61,72 61,95 61,30 61,36 -0,76% 1,05% 6.422.200
21/02/2017 61,84 62,11 61,50 61,83 +0,10% 0,99% 8.503.500
17/02/2017 61,54 62,08 61,17 61,77 +0,47% 1,48% 8.124.400